Posted by Michael Wonder on 08 Mar 2019
FDA grants Genentech’s Tecentriq in combination with Abraxane accelerated approval for people with PD-L1-positive, metastatic triple-negative breast cancer
8 March 2019 - This Tecentriq combination is the first cancer immunotherapy regimen approved for breast cancer.
Genentech today announced the U.S. FDA has granted accelerated approval to Tecentriq (atezolizumab) plus chemotherapy (Abraxane [paclitaxel protein-bound particles for injectable suspension (albumin-bound); nab-paclitaxel]) for the treatment of adults with unresectable locally advanced or metastatic triple-negative breast cancer in people whose tumours express PD-L1, as determined by an FDA-approved test.
This indication is approved under accelerated approval based on progression-free survival.
